Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc

Jason S. Williams,Adam T. Higgins,Katie J. Stott,Carly Thomas,Lydia Farrell,Cleo S. Bonnet,Severina Peneva,Anna V. Derrick,Trevor Hay,Tianqi Wang,Claire Morgan,Sarah Dwyer,Joshua D’Ambrogio,Catherine Hogan,Matthew J. Smalley,Lee Parry,Paul Dyson
DOI: https://doi.org/10.1186/s13578-024-01206-8
2024-03-25
Cell & Bioscience
Abstract:Bacterial cancer therapy was first trialled in patients at the end of the nineteenth century. More recently, tumour-targeting bacteria have been harnessed to deliver plasmid-expressed therapeutic interfering RNA to a range of solid tumours. A major limitation to clinical translation of this is the short-term nature of RNA interference in vivo due to plasmid instability. To overcome this, we sought to develop tumour-targeting attenuated bacteria that stably express shRNA by virtue of integration of an expression cassette within the bacterial chromosome and demonstrate therapeutic efficacy in vitro and in vivo.
biochemistry & molecular biology
What problem does this paper attempt to address?